Valeant

Tom Shepherd named CEO of Bioaster

Monday, September 16, 2013 08:47 AM

Dr. Tom Shepherd has been appointed chief executive officer of Bioaster, a Technology Research Institute focused on infectious diseases and microbiology

More... »

Valeant Pharmaceuticals to acquire Bausch + Lomb

Tuesday, May 28, 2013 02:14 PM

Valeant Pharmaceuticals International, based in Quebec, will acquire Rochester, N.Y.-based Bausch + Lomb, the global eye health company, for $8.7 billion in cash.

More... »

Merz Pharma Group withdraws proposal to acquire Obagi

Monday, April 8, 2013 02:01 PM

Merz Pharma Group has withdrawn its non-binding proposal to acquire all of the outstanding common stock of Obagi Medical Products for $22 per share in cash.

More... »

De Silva named president and CEO of Endo Health Solutions

Wednesday, February 27, 2013 11:25 AM

Endo Health Solutions, a Malvern, Penn.-based diversified healthcare company, has named Rajiv De Silva as president and CEO, effective March 18. De Silva, who will also join the Endo board of directors, succeeds David Holveck, who is retiring.

More... »

Valeant acquires Visudyne from QLT

Tuesday, September 25, 2012 10:57 AM

Valeant Pharmaceuticals International, a multinational specialty pharmaceutical company, has acquired Visudyne, used to treat abnormal growth of leaky blood vessels in the eye caused by wet age-related macular degeneration, from QLT.

More... »

Valeant to acquire Medicis, strengthen dermatology offerings

Tuesday, September 4, 2012 12:36 PM

Montreal-based Valeant Pharmaceuticals International and Medicis Pharmaceutical of Scottsdale, Ariz., have entered into a definitive agreement under which Valeant will acquire all of the outstanding common stock of Medicis for $44 per share in cash. The transaction, which values Medicis' common stock at approximately $2.6 billion, was unanimously approved by the boards of both companies. The $44 price represents a 39% premium to Medicis' closing share price Friday, Aug. 31, the last trading day prior to the announcement, and a 31% premium to the three-month average trading price. The transaction is expected to close in the first half of 2013.

More... »

Valeant Pharmaceuticals to acquire OraPharma

Friday, June 15, 2012 01:42 PM

Valeant Pharmaceuticals International has agreed to acquire OraPharma, a Horsham, Penn.-based specialty oral health company that develops and commercializes products that improve and maintain oral health, from Water Street Healthcare Partners, a private equity firm focused exclusively on the health care industry. 

More... »

Valeant acquires Atlantis Pharma assets

Wednesday, April 18, 2012 02:59 PM

Valeant Pharmaceuticals International has signed an agreement to acquire certain assets from Atlantis Pharma, a branded generics pharmaceutical company in Mexico, for approximately $71 million.

More... »

Eisai partners with PharmaSwiss on chemo agent distribution

Monday, April 9, 2012 02:19 PM

Eisai Europe, the Tokyo-based subsidiary of Eisai, has entered into an agreement with PharmaSwiss, the Switzerland-based division of Valeant Pharmaceuticals International, to promote and distribute the Eisai's novel anticancer agent Halaven (eribulin mesylate) in a number of Central and Eastern European (CEE) countries.

More... »

Valeant moves global headquarters to Quebec

Wednesday, April 4, 2012 01:48 PM

Valeant Pharmaceuticals International is moving its global headquarters to the Montreal region and establishing an R&D center of excellence for consumer dermatologyin nearby Laval, Quebec.

More... »